Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593108 | 0.83 | ALDH1A1 (0.34) | HTR1ASLC6A2SLC6A3JAK2JAK1 | |
| SCHEMBL4858969 | 0.76 | CALCRL (0.40) | PARP1PARP2 | |
| SCHEMBL6802072 | 0.70 | HTR1A (0.39) | HTR1ASLC6A2SLC6A3PARP1 | |
| SCHEMBL4247434 | 0.64 | GRM5 (0.38) | KDM4E | |
| SCHEMBL6804434 | 0.62 | KDM4E (0.33) | KDM4EALPL | |
| SCHEMBL4593110 | 0.61 | CALCRL (0.38) | — | |
| SCHEMBL4593261 | 0.61 | CALCRL (0.48) | — | |
| SCHEMBL31507243 | 0.60 | PARP1 (0.46) | PARP1CHEK1PARP2PARP3 | |
| SCHEMBL11127227 | 0.58 | SIGMAR1 (0.53) | SLC6A3 | |
| SCHEMBL4862841 | 0.57 | BTK (0.40) | PARP1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | HTR1A 171/4885SLC6A2 2782/4885SLC6A3 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.